Sarah A. Reda

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/d2a5b100-504e-11ef-931e-8373c6b518fb.jpg

First Name

Sarah

Last Name

Reda

NPI

1003304510

Faculty ID

17794

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

186405

Visit Type ID

2499

Is Open Scheduling

On

Sriram Machineni

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/c68653a0-bec9-11ee-aa99-759018b444d6.jpg

First Name

Sriram

Last Name

Machineni

NPI

1750350666

Faculty ID

17510

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Machineni obtained his medical degree from the All India Institute of Medical Sciences in New Delhi, followed by a residency in internal medicine at the State University of New York at &nbsp;Buffalo. He served as chief resident and primary care teaching physician at Buffalo General Hospital. He subsequently completed a clinical and research fellowship in obesity medicine and metabolism at Massachusetts General Hospital/ Harvard Medical School and stayed on as an instructor. Dr. Machineni studied energy balance and body fat regulation in animal models allowing the interpretation of clinical research findings and phenotypes in the context of physiology.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Machineni moved to the University of North Carolina at Chapel Hill (UNC) to start a clinical obesity program for treatment, education, and pharmaceutical clinical obesity trials. During his term at UNC, he helped create an obesity primary care network in central North Carolina. He was recruited to Montefiore Medical Center to develop a new medical obesity program.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-family: Calibri, sans-serif;">The Fleischer Institute Medical Weight Center at Montefiore Einstein, founded by Dr. Machineni, is designed to support clinical, educational, and research endeavors in the field of obesity medicine. The program leverages individual variations in response to treatments and uses multiple modalities for weight reduction to treat the comorbidities of obesity and improve quality of life. Special programs are available for individuals who need to lose weight to quality for medical and surgical procedures. The Medical Weight Center works closely with the Montefiore bariatric surgery program to offer a broad spectrum of treatment modalities.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-family: Calibri, sans-serif;">Dr. Machineni has clinical expertise in the m</span><span style="font-family: Calibri, sans-serif; font-size: 12pt;">ultidisciplinary management of obesity, anti-obesity medications, and post-bariatric medical complications, including nutritional deficiencies, hypoglycemia, weight regain, malabsorption, and diarrhea. He</span><span style="font-family: Calibri, sans-serif;">&nbsp;is among a handful of physicians in the New York area with Castle Connolly Top Doctors designation in obesity medicine.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p>1: Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H,Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; <strong>SURMOUNT-2 investigators</strong>.Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Jun 26:S0140-6736(23)01200-X. doi:10.1016/S0140-6736(23)01200-X. Epub ahead of print. PMID: 37385275.</p>
<p>2: Pagidipati NJ, Mulder H, Chiswell K, Lampron Z, Jones WS, <strong>Machineni S</strong>,Waitman LR, Mongraw-Chaffin M, Waterman F, Kumar N, Ramasamy A, Smolarz G,Peterson ED, O'Brien E. Evaluation of weight change and cardiometabolic risk factors in a real-world population of US adults with overweight or obesity. PrevMed. 2023 May;170:107496. doi:10.1016/j.ypmed.2023.107496. Epub 2023 Mar 29.PMID: 36997096.</p>
<p>3: Ro SJ, Lackey AR, Aymes SE, McCauley JL, Davis TC, Wang R, Stanley W, Ratner SP, <strong>Machineni S</strong>, Fiscus LC. Impact of a Community-Based Weight Management Program in a North Carolina Health Care System. Fam Med. 2023 Mar;55(3):189-194.doi: 10.22454/FamMed.2023.603918. Epub 2023 Jan 31. PMID: 36888674.</p>
<p>4: Aronne LJ, Bramblette S, Ingelfinger JR, Jastreboff AM, <strong>Machineni S,</strong> Massie N, Rosen CJ. When Weight Impacts Health. N Engl J Med. 2023 Jan 12;388(2):e2. doi: 10.1056/NEJMp2215794. PMID: 36630621.</p>
<p>5: Aronne LJ, Bramblette S, Huett-Garcia A, Ingelfinger JR, Jastreboff AM, <strong>Machineni S</strong>, Massie N, Rosen CJ. Weight and Health - Pathophysiology and&nbsp;Therapies. N Engl J Med. 2022 Dec 15;387(24):e62. doi: 10.1056/NEJMp2214423. PMID: 36516089.</p>
<p>6: le Roux CW, Zhang S, Aronne LJ, Kushner RF, Chao AM, <strong>Machineni S</strong>, Dunn J, Chigutsa FB, Ahmad NN, Bunck MC. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring). 2023 Jan;31(1):96-110. doi: 10.1002/oby.23612. Epub 2022 Dec 7. PMID: 36478180; PMCID: PMC10107501.</p>
<p>7: Bionic Pancreas Research Group; Russell SJ, Beck RW, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro CA, Li Z, Calhoun P, Wadwa RP, Buckingham B, Zhou K,Daniels M, Raskin P, White PC, Lynch J, Pettus J, Hirsch IB, Goland R, Buse JB,Kruger D, Mauras N, Muir A, McGill JB, Cogen F, Weissberg-Benchell J, Sherwood JS, Castellanos LE, Hillard MA, Tuffaha M, Putman MS, Sands MY, Forlenza G, Slover R, Messer LH, Cobry E, Shah VN, Polsky S, Lal R, Ekhlaspour L, Hughes MS, Basina M, Hatipoglu B, Olansky L, Bhangoo A, Forghani N, Kashmiri H, Sutton F, Choudhary A, Penn J, Jafri R, Rayas M, Escaname E, Kerr C, Favela-Prezas R, Boeder S, Trikudanathan S, Williams KM, Leibel N, Kirkman MS, Bergamo K, Klein KR, Dostou JM, <strong>Machineni S</strong>, Young LA, Diner JC, Bhan A, Jones JK, Benson M, Bird K, Englert K, Permuy J, Cossen K, Felner E, Salam M, Silverstein JM, Adamson S, Cedeno A, Meighan S, Dauber A. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. 2022 Sep 29;387(13):1161-1172. doi: 10.1056/NEJMoa2205225. PMID: 36170500; PMCID: PMC10028490.</p>
<p>8: Perreault L, Davies M, Frias JP, Laursen PN, Lingvay I, <strong>Machineni S</strong>, Varbo A,Wilding JPH, Wallenstein SOR, le Roux CW. Changes in Glucose Metabolism andGlycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg AmongParticipants With Prediabetes in the STEP Program. Diabetes Care. 2022 Oct1;45(10):2396-2405. doi: 10.2337/dc21-1785. PMID: 35724304; PMCID: PMC9862484.</p>
<p>9: Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A,Zhang S, Liu B, Bunck MC, Stefanski A; <strong>SURMOUNT-1 Investigators</strong>. TirzepatideOnce Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.</p>
<p>10: Klein KR, Freeman JLR, Dunn I, Dvergsten C, Kirkman MS, Buse JB, Valcarce C;<strong>SimpliciT1 research group</strong>. The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes. Diabetes Care. 2021 Apr;44(4):960-968. doi:10.2337/dc20-2684. Epub 2021 Feb 23. PMID:33622669; PMCID: PMC7985421.</p>
<p>11: Melanie Davies, Louise F&aelig;rch, Ole K Jeppesen, Arash Pakseresht, Sue D Pedersen, Leigh Perreault, Julio Rosenstock, Iichiro Shimomura, Adie Viljoen, Thomas A Wadden, Ildiko Lingvay; <strong>STEP 2 Study Group</strong>.&nbsp; Semaglutide 2&middot;4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 13;397(10278):971-984. PMID: 33667417.</p>
<p>12: Rosman L, Armbruster T, Kyazimzade S, Tugaoen Z, Mazzella AJ, Deyo Z, Walker J, <strong>Machineni S,</strong> Gehi A. Effect of a virtual self-management intervention for atrial fibrillation during the outbreak of COVID-19. Pacing Clin Electrophysiol. 2021 Mar;44(3):451-461. doi: 10.1111/pace.14188. Epub 2021 Feb 17. PMID: 33565642; PMCID: PMC8014277.</p>
<p>13: Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; <strong>STEP 3 Investigators.</strong> Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 Feb 24. PMID: 33625476; PMCID: PMC7905697.</p>
<p>14: Jensen SM, Thompson RE, <strong>Machineni S,</strong> Overby DW, Farrell TM. Refractory Hypocalcemia Following Stomach Intestinal Pylorus-Sparing Bariatric Surgery and Thyroidectomy: Successful Management With Creation of a Proximal Roux-en-Y Gastric Bypass. Am Surg. 2021 Apr;87(4):576-580. doi: 10.1177/0003134820952427. Epub 2020 Oct 30. PMID: 33125276.</p>
<p>&nbsp;</p>
<p>15: Kushner RF, Batsis JA, Butsch WS, Davis N, Golden A, Halperin F, Kidambi S, <strong>Machineni S,</strong> Novick M, Port A, Rubino DM, Saunders KH, Shapiro Manning L, Soleymani T, Kahan S. Weight History in Clinical Practice: The State of the Science and Future Directions. Obesity (Silver Spring). 2020 Jan;28(1):9-17. doi: 10.1002/oby.22642. PMID: 31858735.</p>
<p>16: Kushner RF, Butsch WS, Kahan S, <strong>Machineni S,</strong> Cook S, Aronne LJ. Obesity Coverage on Medical Licensing Examinations in the United States. What Is Being Tested? Teach Learn Med. 2017 Apr-Jun;29(2):123-128. doi:10.1080/10401334.2016.1250641. Epub 2016 Dec 29. PMID: 28033472.</p>
<p>17: Carmody JS, Ahmad NN, <strong>Machineni S,</strong> Lajoie S, Kaplan LM. Weight Loss After RYGB Is Independent of and Complementary to Serotonin 2C Receptor Signaling in Male Mice. Endocrinology. 2015 Sep;156(9):3183-91. doi: 10.1210/en.2015-1226. Epub 2015 Jun 11. PMID: 26066076; PMCID: PMC4541621.</p>
<p>18: Liou AP, Paziuk M, Luevano JM Jr, <strong>Machineni S,</strong> Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013 Mar 27;5(178):178ra41. doi:10.1126/scitranslmed.3005687. PMID: 23536013; PMCID: PMC3652229.</p>
<p>19: Bose M, Teixeira J, Olivan B, Bawa B, Arias S, <strong>Machineni S,</strong> Pi-Sunyer FX, Scherer PE, Laferr&egrave;re B. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes. 2010 Mar;2(1):47-55. doi: 10.1111/j.1753-0407.2009.00064.x. PMID: 20676394; PMCID: PMC2910618.</p>
<p>20: Bose M, <strong>Machineni S,</strong> Oliv&aacute;n B, Teixeira J, McGinty JJ, Bawa B, Koshy N, Colarusso A, Laferr&egrave;re B. Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding. Obesity (Silver Spring). 2010 Jun;18(6):1085-91. doi: 10.1038/oby.2009.473. Epub 2010 Jan 7.PMID: 20057364; PMCID: PMC2877144.</p>

EMR ID

179058

Is Open Scheduling

Off

Anna Y. Zolotnitskaya

https://assets.montefioreeinstein.org/profiles/images/Zolotnitskaya_Anna_MD_2x_0.jpg

First Name

Anna

Last Name

Zolotnitskaya

NPI

1316949100

Faculty ID

1899

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

EMR ID

31006

Biography

<p>Anna Zolotnitskaya, MD, is Medical Director, Pediatric Dialysis at the Children&rsquo;s Hospital at Montefiore Einstein and Assistant Professor, Pediatrics at our Albert Einstein College of Medicine. Dr. Zolotnitskaya&rsquo;s clinical focus is on pediatric dialysis and pediatric renal transplantation. She leads a multidisciplinary dialysis team that provides patient-centered, evidence-based care for children and young adults with end-stage kidney disease. </p><p>After obtaining her Doctor of Medicine at St. Petersburg Pediatric Academy in St. Petersburg, Russia, in 1983, Dr. Zolotnitskaya completed her pediatrics internship at the same institution in 1984. She remained there to complete her pediatrics residency in 1989, before completing an additional pediatrics residency at Soroka Medical Center in Beer-Sheva, Israel, in 1994. Following this, Dr. Zolotnitskaya completed a pediatric nephrology fellowship at Montefiore Einstein in 1998, followed by an additional pediatrics residency at Columbia University College of Physicians and Surgeons, St. Luke&rsquo;s-Roosevelt Hospital in 2001. </p><p>Dr. Zolotnitskaya has been principal investigator and co-investigator in clinical trials that investigate medications employed for the care of children with advanced chronic kidney disease. Her work has been published in numerous peer-reviewed journals and abstracts, and she has given several invited presentations. She is also a reviewer for the <em>Journal of Pediatrics: Clinical Practice</em>. </p><p>Dr. Zolotnitskaya is board certified by the American Board of Pediatric Nephrology, the American Board of Pediatrics and the Israeli Board of Pediatrics. She is a member of the American Academy of Pediatrics, the American Society of Nephrology and the American Society of Pediatric Nephrology.

</p>

Is Open Scheduling

Off

Beatrice Y. Wong

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/b4012680-c3c5-11eb-9ea2-7374238588d1.jpg

First Name

Beatrice

Last Name

Wong

NPI

1033656541

Faculty ID

16257

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

95560

Visit Type ID

2499

Is Open Scheduling

On

Lucia R. Wolgast

https://assets.montefioreeinstein.org/profiles/images/Wolgast_Lucia_MD_2x.jpg

First Name

Lucia

Last Name

Wolgast

NPI

1770881260

Faculty ID

12874

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Hematology and Coagulation<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Antiphospholipid Syndrome<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

4811

Is Open Scheduling

Off

Ana Y. Valdivia

https://assets.montefioreeinstein.org/profiles/images/physphoto/Valdivia_Ana_MD_420x504.jpg

First Name

Ana

Last Name

Valdivia

NPI

1184728404

Faculty ID

8283

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4272

Biography

<p>Ana Y. Valdivia, MD, is an attending physician at Montefiore Einstein and Assistant Professor, Diagnostic Radiology at our Albert Einstein College of Medicine. Dr. Valdivia&rsquo;s clinical focus involves all aspects of nuclear medicine, with a particular focus on positron emission tomography&ndash;computed tomography (PET-CT).</p><p>After receiving her Bachelor of Science in chemistry at the University of Puerto Rico in 1990, Dr. Valdivia attended Universidad Central del Caribe School of Medicine, earning her Doctor of Medicine in 1994. She completed her internal medicine residency at Veterans Affairs Medical Center in 1997, followed by her nuclear medicine residency at Mount Sinai Medical Center in 1999.</p><p>Dr. Valdivia&rsquo;s research involves PET-CT, frequently focusing on brain imaging. She has shared her research through peer-reviewed journals, book chapters, abstracts, exhibits, and oral and poster presentations. She is also an invited reviewer for the International Journal of Surgery.</p><p>Dr. Valdivia is board certified by the American Board of Internal Medicine and the American Board of Nuclear Medicine. She is a member of the Society of Nuclear Medicine and the American College of Radiology.</p>

Is Open Scheduling

Off

Berrin Ustun

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ustun_Berrin_MD_11119532.jpg

First Name

Berrin

Last Name

Ustun

NPI

1568789394

Faculty ID

13617

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5648

Is Open Scheduling

Off

Henry Michael Ushay

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ushay_Michael_MD_420x504.jpg

First Name

Henry

Last Name

Ushay

NPI

1558332007

Faculty ID

10275

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Pediatric critical care medicine with a special emphasis on respiratory failure; shock resuscitation; cardiac intensive care; intensive care of pediatric oncology patients; extracorporeal support for children with respiratory and cardiovascular failure

Research Focus

Leadership and direction of the 16-bed Pediatric Critical Care Unit of The Children&rsquo;s Hospital at Montefiore; improving medication safety; respiratory physiology; advances in the management of respiratory failure in children; shock; medical ethics

Elsevier Profile

EMR ID

4763

Biography

<p>Dr. Ushay is Professor of Clinical Pediatrics in the Albert Einstein College of Medicine. He is a Fellow of the American Academy of Pediatrics as well as a Fellow of the American College of Critical Care Medicine. </p><p>After obtaining a PhD in Chemistry from Columbia University, Dr. Ushay received his MD from UMDNJ-New Jersey Medical School and completed a Pediatrics residency in the Montefiore-Jacobi-Einstein program. After serving as Chief Resident and a Fellow in Pediatric Pulmonology at Montefiore, he completed a Pediatric Critical Care Fellowship at New York Hospital/Cornell Medical Center in 1993. He was a faculty member at NewYork-Presbyterian and Memorial Sloan-Kettering Hospitals from 1993 to 2005, and he served as Pediatric Critical Care Medicine Fellowship Program Director and Medical Director of the Pediatric Observation Unit at Memorial Sloan-Kettering Cancer Center. </p><p>In 2005 Dr. Ushay became Director of the Pediatric Critical Care Unit in The Children&rsquo;s Hospital at Montefiore. Dr. Ushay is involved in increasing pediatric ICU surge capacity through the New York City Pediatric Disaster Coalition, serving on its Central Leadership Council and teaching the Pediatric Fundamental Critical Care Support Course. Through the National Institute of Child Health and Human Development, Dr. Ushay works on employing medical countermeasures safely for children in the event of chemical, biological or radiological disaster. Sponsored by Surgeons of Hope and Children&rsquo;s HeartLink, Dr. Ushay has worked as a cardiac intensivist in Cambodia, Africa, China and Nicaragua. </p>

Is Open Scheduling

Off

Yaron Tomer

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/e3b1f380-8c61-11ed-9474-c3e3b839843d.jpg

First Name

Yaron

Last Name

Tomer

NPI

1982662334

Faculty ID

14884

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Yaron Tomer is the Marilyn and Stanley M. Katz Dean at Albert Einstein College of Medicine and Chief Academic Officer at Montefiore Medicine.</p>
<p>He received his M.D. degree magna cum laude from the Sackler School of Medicine of Tel Aviv University and trained in Internal Medicine at Sheba Medical Center, Israel, and in Endocrinology at the Icahn School of Medicine at Mount Sinai in New York. Prior to joining Montefiore Einstein in March 2016, he was Chief of the Division of Endocrinology, Diabetes, and Bone Disease at Mount Sinai.</p>
<p>Dr. Tomer has served on the editorial boards of <em>Endocrinology </em>and <em>The Journal of Clinical Endocrinology and Metabolism</em>, among others. He is a member of the American Society for Clinical Investigation and a Fellow of the American College of Physicians. Dr. Tomer is the recipient of several prestigious awards, including the American Thyroid Association&rsquo;s Sidney H. Ingbar Distinguished Lectureship Award, as well as its Van Meter Award.</p>
<h3>Research</h3>
<p>Dr. Tomer&rsquo;s research program focuses on the immunogenetic, epigenetic, and environmental mechanisms underlying thyroid autoimmunity, and type 1 diabetes, and on targeting these mechanisms in order to develop novel therapies. His group made several discoveries including identifying new genes and mechanisms underlying the strong association between type 1 diabetes and autoimmune thyroiditis; demonstrating that CD40 and thyroglobulin are major susceptibility genes for thyroid autoimmunity; identifying a unique amino acid variant in the peptide binding pocket of HLA-DR that is key for the development of thyroid autoimmunity; dissecting the epigenetic mechanisms by which polymorphisms in the thyroglobulin and TSHR genes interact with environmental agents (e.g. viruses) to trigger thyroid autoimmunity; and identifying a novel small molecule that can block antigen presentation in autoimmune thyroiditis.</p>
<h3>Current Projects</h3>
<ol role="list">
<li><strong>Genetic and epigenetic studies in thyroid autoimmunity</strong><br />The Tomer lab mapped several susceptibility genes for autoimmune thyroid diseases (AITD) including CD40, thyroglobulin, and TSHR. Recent data suggest that variants in regulatory regions of some of these genes interact epigenetically with environmental factors (e.g., viral infections) to trigger disease. Current studies are using epigenomic screening, including whole genome methylation studies and ChiP-seq analyses to study these genetic-epigenetic interactions.</li>
<li><strong>Epigenetic studies in type 1 diabetes</strong><br />Similar studies are utilizing epigenomic screening to analyze epigenetic interactions between known type 1 diabetes susceptibility genes and interferon alpha, a key cytokine secreted during viral infections.</li>
<li><strong>Translational studies in autoimmune thyroiditis (AITD) and type 1 diabetes</strong><br />The Tomer lab discovered that the presence of arginine at position beta-74 of the peptide binding pocket of HLA-DR is critical for the development of AITD. This discovery led to a translational project aimed at blocking thyroid antigen presentation to T-cells by the arginine beta-74 HLA-DR peptide binding pocket as a potential therapy for AITD. Recently, the Tomer lab identified a small molecule, Cepharanthine, that can block antigen presentation and suppress AITD in mouse models. Similar studies are performed in type 1 diabetes where the aim is to block the HLA-DQ8 peptide binding pocket from presenting insulin peptides to T-cells as a novel strategy to treat autoimmune diabetes.</li>
<li><strong>Genetic and functional analyses of autoimmune polyglandular syndrome (APS) type 3</strong><br />The co-occurrence of type 1 diabetes and autoimmune thyroiditis in the same individual is considered a variant of the APS type 3 syndrome. The Tomer lab discovered several new susceptibility genes for APS3. The lab is now analyzing the mechanisms by which these genes predispose to disease.</li>
<li><strong>The role of viruses in triggering autoimmune thyroiditis and type 1 diabetes</strong><br />Certain infections, such as hepatitis C, are associated with autoimmune thyroiditis and diabetes. Current studies are aimed at dissecting the mechanisms by which interferon alpha, the primary cytokine secreted during viral infections, can trigger autoimmune thyroiditis and diabetes in genetically susceptible individuals.</li>
</ol>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<ol role="list">
<li>Menconi F, Monti MC, Greenberg DA, Oashi T, Osman R, Davies TF, Ban Y, Jacobson EM, Concepcion ES, Li CW, <span class="underline">Tomer Y</span>. Molecular amino acid signatures in the MHC class II peptide binding pocket predispose to autoimmune thyroiditis in humans and in mice. Proc Natl Acad Sci USA 2008; 105: 14034-14039.</li>
<li>Jacobson EM, Yang H, Menconi F, Wang R, Osman R, Skrabanek L, Li CW, Fadlalla M, Gandhi A, Chaturvedi V, Smith EP, Schwemberger S, Osterburg A, Babcock GF, <span class="underline">Tomer Y</span>. Employing a recombinant HLA-DR3 expression system to dissect MHC II-thyroglobulin peptide dynamism: A genetic, biochemical, and reverse immunological perspective. J Biol Chem 2009; 284: 34231-34243.</li>
<li>Villano MJ, Huber AK, Greenberg DA, Golden BK, Concepcion E, <span class="underline">Tomer Y</span>. Autoimmune thyroiditis and diabetes: Dissecting the joint genetic susceptibility in a large cohort of multiplex families. J Clin Endocrinol Metab 2009; 94: 1458-1466.</li>
<li>Menconi F, Osman R, Monti MC, Greenberg DA, Concepcion ES, <strong>Tomer Y</strong>. Shared molecular amino acid signature in the HLA-DR peptide binding pocket predisposes to both autoimmune diabetes and thyroiditis. Proc Natl Acad Sci USA 2010; 107: 16899-16903.</li>
<li>Menconi F, Huber A, Osman R, Concepcion E, Jacobson EM, Stefan M, David, CS, <span class="underline">Tomer Y</span>. Tg.2098 is a major human thyroglobulin T-cell epitope. J Autoimmun 2010; 35: 45-51.</li>
<li>Stefan M, Jacobson EM, Huber AK, Greenberg DA, Li CW, Skrabanek L, Concepcion E, Fadlalla M, Ho K, <span class="underline">Tomer Y</span>. Novel variant of thyroglobulin promoter triggers thyroid autoimmunity through an epigenetic interferon alpha-modulated mechanism. J Biol Chem 2011; 286: 31168-31179.</li>
<li>Huber AK, Finkelman FD, Li CW, Concepcion E, Smith E, Jacobson E, Latif R, Keddache M, Zhang W, <span class="underline">Tomer Y</span>. Genetically driven target tissue overexpression of CD40: A novel mechanism in autoimmune disease. J Immunol 2012; 189: 3043-3053.</li>
<li>Stefan M, Wei C, Lombardi A, Li CW, Concepcion ES, Inabnet WB 3rd, Owen R, Zhang W, <span class="underline">Tomer Y</span>. Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity. Proc Natl Acad Sci USA 2014; 111: 12562-12567.</li>
<li><span class="underline">Tomer Y</span>, Dolan LM, Kahaly G, Divers J, D&rsquo;Agostino Jr. RB, Imperatore G, Dabelea D, Marcovina S, Black MH, Pihoker C, Hasham A, Hammerstad SS, Greenberg DA, Lotay V, Zhang W, Monti MC, Matheis N. Genome wide identification of new genes and pathways in patients with autoimmune thyroiditis and type 1 diabetes. J Autoimmun 2015; 60: 32-39.</li>
<li>Li CW, Menconi F, Osman R, Mezei M, Jacobson EM, Concepcion E, David CS, Kastrinsky DB, Ohlmeyer M, <strong>Tomer Y</strong>. Identifying a small molecule blocking antigen presentation in autoimmune thyroiditis. J Biol Chem 2016; 291: 4079-4090.</li>
<li>Li CW, Osman R, Menconi F, Concepcion ES, <span class="underline">Tomer Y</span>. Flexible peptide recognition by HLA-DR triggers specific autoimmune T-cell responses in autoimmune thyroiditis and diabetes. J Autoimmun 2017; 76: 1-9.</li>
<li>Faustino LC, Lombardi A, Madrigal-Matute J, Owen RP, Libutti SK, <span class="underline">Tomer Y</span>. Interferon alpha triggers autoimmune thyroid diseases via lysosomal-dependent degradation of thyroglobulin. J Clin Endocrinol Metab 2018; 103: 3678-3687.</li>
<li>Stefan-Lifshitz, M, Karakose E, Cui L, Ettela A, Yi Z, Zhang W, <span class="underline">Tomer Y</span>. Epigenetic modulation of &beta;-cells by interferon-&alpha; via PNPT1-miR26a-TET2 triggers autoimmune diabetes. JCI Insight 2019; 4: e126663.</li>
<li>Li CW, Osman R, Menconi F, Concepcion E, <span class="underline">Tomer Y</span>. Cepharanthine blocks TSH receptor peptide presentation by HLA-DR3: Therapeutic implications to Graves&rsquo; disease. J Autoimmun 2020; 108: 102402.</li>
<li>Lombardi, A, Concepcion E, Hou H, Arib H, Mezei M, Osman R, <span class="underline">Tomer Y</span>. Retro-inverso D-peptides as a novel targeted immunotherapy for type 1 diabetes. J Autoimmune 2020; 115: 102543.</li>
<li>Li CW, Sachidanandam R, Jayaprakash A, Yi Z, Zhang W, Stefan-Lifshitz M, Concepcion E, <span class="underline">Tomer Y</span>. Identification of new rare variants associated with familial autoimmune thyroid diseases by deep sequencing of linked loci. J Clin Endocrinol Metab 2021; 12: 691781.</li>
<li>Ye J, Stefan-Lifshitz M, <span class="underline">Tomer Y</span>. Genetic and environmental factors regulate the type 1 diabetes gene CTSH via differential DNA methylation. J Biol Chem 2021; 296: 100774.</li>
<li>Li CW, Osman R, Menconi F, Faustino LC, Kim K, Clarke OB, Hou H, <span class="underline">Tomer Y</span>. Cepharanthine blocks presentation of thyroid and islet peptides in a novel humanized autoimmune diabetes and thyroiditis mouse model. Front Immunol 2021; 12: 796552.</li>
</ol>

EMR ID

81697

Is Open Scheduling

Off

Vafa Tabatabaie

https://assets.montefioreeinstein.org/profiles/images/Tabatabaie_Vafa_MD_2x.jpg

First Name

Vafa

Last Name

Tabatabaie

NPI

1861789976

Faculty ID

13732

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Vafa Tabatabaie received her medical degree from Shahid Beheshti Medical University in Tehran, Iran. After several years of research on thyroid cancer in Toronto, Canada, she came to Montefiore in 2007, initially as a clinical observer and then as a researcher in the Division of Endocrinology under the direction of Drs. Norman Fleischer and Martin Surks. She graduated from the Internal Medicine Residency Program in 2011, during which her enthusiasm and teaching skills were recognized with the Award for Outstanding House Officer in Internal Medicine. She then completed her Endocrinology Fellowship in 2013 and joined the Einstein Montefiore Division of Endocrinology faculty later that year.</p>
<p>Dr. Tabatabaie is the Clinical Director for Division of Endocrinology.&nbsp;She is also the Director of Fracture Liaison Services, a multi-disciplinary team of Endocrinologist, Geriatricians and Orthopedic Surgeons focused on secondary prevention of osteoporotic fractures. &nbsp;Dr Tabatabaie is one of the founding members of Transgender Interest Group at Montefiore/Einstein. Her clinical research interests include endocrine issues in the elderly, especially metabolic bone disease and osteoporosis, as well as thyroid cancer. She has contributed to the field of endocrinology by writing journal articles, presenting posters at national endocrine meetings, and mentoring medical students, residents and fellows. In recognition of her contributions to medical education, she was accepted into Leo M Davidoff Society in 2019. She also received Department of Medicine's Humanism Award in 2018.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p><strong>Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort</strong></p>
<p>Cancers,&nbsp;<span style="caret-color: #5b616b; color: #5b616b; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">2021 Mar 23;13(6):1464</span></p>
<p>&nbsp;</p>
<p><strong>Are We Responding Effectively to Bone Mineral Density Loss and Fracture Risk in People with Epilepsy?</strong></p>
<p>Epilepsia Open, 2020 Apr 14;5(2): 240-247</p>
<p>&nbsp;</p>
<p><strong>Changes in Bone Mineral Density During 5 Years of Adjuvant Treatment in Premenopausal Breast Cancer Patients</strong></p>
<p>Breast Cancer Research and Treatment, 2020 Feb 19</p>
<p>&nbsp;</p>
<p><strong>Treatment of Diabetic Ketoacidosis and The Weekend Effect at an Urban Tertiary-Care Center</strong></p>
<p>Endocrine Practice,&nbsp;<span style="caret-color: #5b616b; color: #5b616b; font-family: BlinkMacSystemFont, -apple-system, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 16px;">2020 Jun 2;26(6):634-641</span></p>
<p>&nbsp;</p>
<p><strong>Thyroid Storm Presenting as Psychosis</strong></p>
<p>Journal of Investigative Medicine High Impact Case Reports, May 2018</p>
<p>&nbsp;</p>
<p><strong>Medical Optimization of Lumbar Fusion in the Osteoporotic Patient</strong></p>
<p>Archives of Osteoporosis, 2018 March 14: 13 (1): 26</p>
<p>&nbsp;</p>
<p><strong>Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels</strong></p>
<p>Journal Of Clinical Endocrinology and Metabolism. 2016 Aug; 101 (8): 3096-104</p>
<p>&nbsp;</p>
<p><strong>Effects of Testosterone Treatment in Older Men</strong></p>
<p>New England Journal of Medicine, 2016 Feb 18: 374 (7): 611-24</p>
<p>&nbsp;</p>
<p><strong>Recruitment and Screening for the Testosterone Trials</strong></p>
<p>The Journals of Gerontology, 2015 Sep, 70(9): 1105-11</p>
<p>&nbsp;</p>
<p><strong>Association of Sex Hormones with Sexual Function, Vitality, and Physical Function of Symptomatic Older Men with Low Testosterone Levels at Baseline in the Testosterone Trials</strong></p>
<p>Journal of Clinical Endocrinology and Metabolism, 2015 Mar, 100(3):1146-55</p>
<p>&nbsp;</p>
<p><strong>Exceptional Longevity is Associated with Decreased Reproduction</strong></p>
<p>Aging, 2011 Dec, 3(12):1202-5</p>
<p>&nbsp;</p>
<p><strong>Influence of Age and Primary Tumor Size on the Risk for Residual/Recurrent Well-Differentiated Thyroid Carcinoma</strong></p>
<p>Head and Neck, 2009 Jun; 31(6):782-8</p>
<p>&nbsp;</p>
<p><strong>Post-Challenge Hyperglycemia in Older Adults is Associated with Increased Cardiovascular Risk Profile</strong></p>
<p>Journal of Clinical Endocrinology and Metabolism, 2009 May, 94(5):1595-601</p>
<p>&nbsp;</p>
<p><strong>Prognostic Value of Postsurgical Stimulated Thyroglobulin Levels after Initial Radioactive Iodine Therapy in Well-Differentiated Thyroid Carcinoma</strong></p>
<p>Head and Neck, 2008 Jun; 30(6):693-700</p>

EMR ID

5083

Biography

<p>Dr. Vafa Tabatabaie received her medical degree from Shahid Beheshti University of Medical Sciences in Tehran, Iran. After several years of research on thyroid cancer in Toronto, Canada, she came to Montefiore in 2007 as a researcher in the Division of Endocrinology under the direction of Drs. Norman Fleischer and Martin Surks. She graduated from the Internal Medicine Residency Program in 2011, during which her enthusiasm and teaching skills were recognized with the Award for Outstanding House Officer in Internal Medicine, and she completed the Endocrinology Fellowship Program in 2013. She joined the Einstein Montefiore Division of Endocrinology faculty later that year.</p><p>Dr. Tabatabaie is Director of the Fracture Liaison Service at Montefiore Medical Center. Her clinical research interests include endocrine issues in the elderly, especially metabolic bone disease and osteoporosis, as well as thyroid cancer.</p>

Visit Type ID

2499

Is Open Scheduling

On